Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

NCT06574360 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT06574360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06574360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Lead sponsor
China Medical University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 23, 2024
Completion date
March 31, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia